Watching alerts...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What do you honestly think is going to happen here? It hurts to watch you guys think this is going anywhere back to what is was without an RS.
This is huge for the sector! Psychedelic Rally 2.0 incoming!
https://www.washingtonpost.com/business/2023/12/12/mdma-therapy-fda-maps/
This is huge for the sector! Psychedelic Rally 2.0 incoming!
https://www.washingtonpost.com/business/2023/12/12/mdma-therapy-fda-maps/
Not happening Bone... sorry bud...
This shit ticker ran its course a while ago. The best would be an RS to add volume. But the existing holders would be roasted.
Told you to sell almost a year ago but what the hell did I know then. ;)
Definitely hitting NASDAQ
This one is going to a dollar.
Q1 is going to be very nice in 2024... I am loaded
I think the end result will be bigger than the NASDAQ hype to be honest. The valuation will be a true one when they have a product close to market or they get bought out. Either way. Everyone will win buying down here. Phase 2 ;)
Last bit of tree shaking before takeoff.
Good morning. Ready for up up and away? This one will be a nice gemstone to grab and cherish.
Get in now before it goes to a buck!
These BIOTECH are getting ready to hit hard.
Was in for the run - now here for the long haul. You'll make money again here. BIG GAINS COMING!!!
This will hit close to a 1.00 if not more on the anticipation of joining the beloved NASDAQ :)
This is going to pass the peak in time. I rode from IPO to the BIG N and been buying back in... this will be unreal when they are bought out or bring a product to market.
All the shares I have now are riding until one of those two events occur. Enjoy!
Looking good to run here!
No you're not... better count your blessings instead of your shares here bone.
I just keep buying this at these levels. Just set and forget. One of the few I will hold into 2025-2026. They will get bought out or have a product lining up by then.
No way. Will run soon. One more good one in this script!
Got back in hard on this one. Coming soon!
End of year run coming up folks... get back in after the last run.
Hey just by a head count how many of you are gonna lose all you money here holding these hemp fiber bags of lead infused stevia while Ken medicates himself with the delta-9 cbd he bought with your blood money and life savings.
happy weekend! :)
Plenty of time after an RS ;)
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299061/
Common antidepressant escitalopram and psilocybin can be taken together safely: study
https://mugglehead.com/popular-antidepressant-escitalopram-and-psilocybin-can-be-taken-together-safely-study/
Happy Halloween! US Patent US-11801256-B2
Antidepressant-psilocybin co-treatment to assist psychotherapy
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11801256
Ive gobbled up a lot during this low period. Perfectly happy holding for a few years with my new found share floor.
We are not worried about decriminalization WQlf... We want pharmaceuticals and them made in a lab. the naturalists want the decriminalization. FuQ that.
You're not from around here are you?
Yes, but its a bullshit scheme to then short it below the requirement and the cycle continues. LOL!
ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT
https://www.newswire.ca/news-releases/atai-life-sciences-announces-filing-of-early-warning-report-886747079.html
News provided by
atai Life Sciences AG
10 Oct, 2023, 08:00 ET
Share this article
TORONTO, Oct. 10, 2023 /CNW/ - This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023.
On August 31, 2023, IntelGenx announced that, in connection with a non-brokered offering (the "Offering") of units (the "US Units"), each comprised of a US$1,000 principal amount convertible promissory note and 5,405 common stock purchase warrants, IntelGenx had agreed to, among other things: (i) enter into a second amendment (the "Second Amendment") to the amended and restated loan agreement dated as of September 14, 2021 (the "Loan Agreement") to provide, among other things, for the ability for atai to convert the principal and accrued interest outstanding under the Loan Agreement into common stock of IntelGenx ("Shares") at a price of US$0.185 per Share (the "Conversion Feature"); and (ii) enter into an amendment (the "Subscription Agreement Amendment") to the subscription agreement entered into by and between IntelGenx and atai in connection with the Offering, to provide atai with the right (the "Call Option") to purchase up to an additional 6,013 US Units at any time prior to August 31, 2026.
On October 6, 2023, atai and IntelGenx entered into the Second Amendment and the Subscription Agreement Amendment, both effective September 30, 2023 (the "Transaction"). In connection with the Second Amendment, atai and IntelGenx entered into a second amended and restated loan agreement to provide for the Conversion Feature. In connection with the Call Option, atai and IntelGenx entered into the Subscription Agreement Amendment, pursuant to which IntelGenx granted atai the option to purchase up to an additional 7,401 US Units (the "Call Option Units") at any time prior to August 31, 2026. Pursuant to the Subscription Agreement Amendment, the acquisition of any Call Option Units will result in a corresponding reduction in atai's remaining purchase right pursuant to the amended and restated securities purchase agreement dated May 14, 2021 (the "2021 Purchase Right"), with such right to be reduced by the maximum number of Shares issuable in connection with such Call Option Units, and (ii) in the event that the 2021 Purchase Right has been fully or partially exercised such that the aggregate number of Shares issued thereunder together with the number of Shares issuable in accordance with the Call Option would exceed 100,000,000, the number of Shares that may be issued in connection with the Call Option shall be reduced such that the aggregate number of Shares issued thereunder together with the number of Shares issuable in accordance with the Call Option does not exceed 100,000,000. The exercise of the Call Option is subject to the prior approval of the shareholders of IntelGenx.
Immediately prior to the Transaction, excluding Shares issuable upon the conversion of interest that may be outstanding from time to time, atai had ownership and control over securities convertible into approximately 269,152,849 Shares representing approximately 66.2% of the issued and outstanding Shares, on a partially diluted basis. Following the Transaction, assuming the conversion of the outstanding principal balance of the Loan Agreement and/or exercise of the Call Option (including the underlying securities) and excluding Shares issuable upon the conversion of interest that may be outstanding from time to time, atai would beneficially own or control in aggregate 237,732,850 Shares representing approximately 63.4% of the issued and outstanding Shares, on a partially diluted basis.
atai's acquisitions and dispositions were made in connection with atai's existing investment in IntelGenx. In accordance with applicable securities laws, atai may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of IntelGenx in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of IntelGenx and other relevant factors.
An early warning report will be filed under IntelGenx's profile on the SEDAR+ website at www.sedarplus.ca. To obtain more information or to obtain a copy of the early warning report filed in respect of this press release, please contact atai by email at ir@atai.life or by mail at c/o atai Life Sciences AG, Wallstraße 16, 10179, Berlin, Germany.
The mailing address of IntelGenx is located at 6420 Rue Abrams, Saint-Laurent, QC H4S 1Y2, Canada.
SOURCE atai Life Sciences AG
Updated with BS and further slides into the trips after a tiny speed bump. Oh then an RS so they can claim they need to get to over a penny for OTCQB... lol
This will lose you all more money while they play this game. So sad.
not a guess lol
This is getting ready for a hard run. the pullback happened over the past month... a few sold off. Lots accumulated between Dec 2022 and into Early July 2023... get ready boys and girls for a fun fill rip! It's coming!
These are just the previews.
Next week will be the same as last...
You drink to much or smoke too much because there is nothing going on here today. LOL!
One of the few real companies in the OTC... They are Penny Stock Exempt and trade OTCQB. With the share setup and actual direction. I see dollars here.
Yes. Hanging tight here. Very nice chart, but more importantly - good business planning.
Not happening.